SSGJ-716 for healthy adults and people with atopic dermatitis
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine, SSGJ-716, in healthy adults and in people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and how the body reacts to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You weigh at least 110 pounds (if male) or 100 pounds (if female), and your body mass index is between 18 and 28.
- You are generally healthy or have minor health issues that the study doctor says are okay.
- You agree to use highly effective birth control if you are able to get pregnant or if you have a partner who can get pregnant.
- You do not have serious allergies, hepatitis B or C, HIV, or a history of alcohol or drug abuse.
- You are not pregnant or breastfeeding, and you do not use nicotine products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Hear when a new AD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.